Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
03 oct. 2022 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”)...
Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
08 sept. 2022 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing...
Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
11 août 2022 16h30 HE
|
Fortress Biotech, Inc.
Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million Positive results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell...
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation
11 août 2022 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Fortress Biotech Appoints David Jin as Chief Financial Officer
22 juil. 2022 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, July 22, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States
31 mai 2022 08h30 HE
|
Fortress Biotech, Inc.
Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary company, UR-1 Therapeutics Dotinurad (URECE® tablet) was approved in Japan...
Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences
18 mai 2022 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, May 18, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
12 mai 2022 16h01 HE
|
Fortress Biotech, Inc.
Net revenue for first quarter of 2022 increased 106% period-over-period to $23.9 million, a company quarterly record Positive topline results from registration-enabling study of cosibelimab in...
Fortress Biotech to Present at the 21st Annual Needham Virtual Healthcare Conference
07 avr. 2022 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, April 07, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
01 avr. 2022 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, April 01, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...